Semaglutide Patches Need a Different Needle

A patch you press onto your arm instead of a weekly injection is the most requested upgrade for people on semaglutide. A study published September 20, 2026 in the International Journal of Pharmaceutics explains why that patch is harder to build than it looks: the needle shape that works for a small drug molecule barely works at all for a peptide the size of semaglutide, and the two need almost opposite designs.

The researchers were not testing a finished product. They were building a design method: a computer model called finite element analysis, or FEA, which simulates how a solid object bends, breaks, or pushes into a surface before anyone manufactures it. Engineers already use FEA to test bridges and phone cases without building each version by hand. Here, the team used it to screen seven microneedle shapes for how well each one would hold together while punching through skin, before testing the winners on real skin samples in the lab.

Why semaglutide can't just be swallowed or rubbed on

Right now, semaglutide reaches the body one way in most people: a weekly subcutaneous injection, delivered under the skin of the abdomen, thigh, or upper arm. The FDA-approved prescribing information for Wegovy specifies this exact route and schedule^[3]. Peptides like semaglutide are broken down by stomach enzymes if swallowed and are too large to pass through intact skin on their own, which is why the injection has stuck around even as patients ask for alternatives.

A dissolving microneedle patch tries to get around both problems. It is an array of needles a fraction of a millimetre long, molded out of a soluble material with the drug mixed inside. Pressed onto skin, the needles pierce only the outermost, non-living layers, then dissolve there and release their payload. No syringe, no sharps waste, no visit to inject at a specific site. The idea has already worked for smaller molecules and for some vaccines. Peptides the size of semaglutide are the harder case.

The same patch shape does not work for every drug

The September 2026 paper's central finding is that the best microneedle geometry depends heavily on what it is carrying^[1]. The team compared two cargo types: semaglutide, a large peptide molecule, against rizatriptan benzoate, a small-molecule migraine drug roughly a tenth of semaglutide's size. Screening seven candidate shapes by FEA, then confirming the top performers experimentally, the semaglutide-optimized design reached 90.58 percent relative bioavailability, meaning almost as much drug entered the body as an equivalent injected dose would deliver. That is, per the authors, the highest figure reported for a dissolving microneedle carrying a GLP-1 receptor agonist.

The small-molecule design that worked best for rizatriptan looked nothing like the semaglutide winner. It differed in tip sharpness, how much reservoir volume sat at the needle base, and whether the needle dissolved in one stage or several. A sharp, slim needle that dumps a small molecule quickly is a poor match for a bulky peptide that needs a larger reservoir and a slower, staged release to fully diffuse into tissue. Rizatriptan's best design reached 465.40 percent relative bioavailability compared with its usual oral tablet, a far higher number, but oral tablets are a much lower bar to beat than an injection already delivering close to 100 percent of the dose.

This is not the first attempt at a semaglutide patch

Other labs have already tried to solve this from a different angle: the recipe rather than the needle shape. A paper published in July 2026 in AAPS PharmSciTech built semaglutide microneedles from hyaluronic acid, a polymer called PETOX, and L-arginine, aiming for a formulation that keeps the fragile peptide stable while it dissolves^[2]. That version showed sustained release over 12 hours and visible skin penetration in fluorescence-imaged ex-vivo tissue, but the authors flagged that keeping the peptide intact and active during delivery, not just getting it into the skin, remains an open problem.

Put the two papers side by side and a pattern shows up. One group is asking what the needle is made of. The other is asking what shape the needle should be. A workable semaglutide patch will likely need answers to both, and neither team has run a study in a living person yet.

What this means for future GLP-1 patches

A cargo-aware design method matters beyond semaglutide. Every large peptide drug, including tirzepatide, faces the same mismatch between its size and the microneedle shapes that were originally developed for vaccines and small molecules. If a screening method like FEA can predict which needle geometry suits a given peptide before anyone manufactures a physical prototype, it should shorten the path from lab bench to a testable patch for the next drug in line, not only semaglutide.

None of that has happened yet. Faster does not mean fast: cargo-aware design is a step that comes before animal studies, which come before human trials, which come before a regulator reviews anything for approval.

What we don't yet know

Both studies behind this article are lab-stage work. The FEA paper tested its winning designs on skin samples, not on a living animal or a person, so there is no data yet on how the patch performs on real, moving, healing skin, or on pain, irritation, or dosing consistency across repeated use. Neither paper reports a timeline for animal or human testing. Anyone considering waiting for a semaglutide patch instead of starting or continuing an injectable GLP-1 medicine should talk to a prescriber about the treatments actually available now, not a delivery method still confined to lab benches.